{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:23:09Z","timestamp":1788009789548,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T00:00:00Z","timestamp":1310083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s00393-011-0830-6","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T12:17:33Z","timestamp":1309954653000},"page":"549-552","source":"Crossref","is-referenced-by-count":15,"title":["Nierensch\u00e4digung durch Methotrexat?","Is methotrexate nephrotoxic?"],"prefix":"10.1007","volume":"70","author":[{"given":"U.","family":"Erdbr\u00fcgger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,8]]},"reference":[{"key":"830_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","volume":"64","author":"Yazici","year":"2005","unstructured":"Yazici Y, Sokka T, Kautiainen H et al (2005) Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 64:207\u2013211","journal-title":"Ann Rheum Dis"},{"key":"830_CR2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","volume":"30","author":"Bannwarth","year":"1996","unstructured":"Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J (1996) Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 30:194\u2013210","journal-title":"Clin Pharmacokinet"},{"key":"830_CR3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s10067-007-0625-y","volume":"26","author":"Karstila","year":"2007","unstructured":"Karstila K, Korpela M, Sihvonen S, Mustonen J (2007) Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study. Clin Rheumatol 26:2089\u20132095","journal-title":"Clin Rheumatol"},{"key":"830_CR4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/rheumatology\/kem370","volume":"47","author":"Karie","year":"2008","unstructured":"Karie S, Gandjbakhch F, Janus N et al (2008) Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology 47:350\u2013354","journal-title":"Rheumatology"},{"key":"830_CR5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CNP64315","volume":"64","author":"Izzedine","year":"2005","unstructured":"Izzedine H, Launay-Vacher V, Karie S et al (2005) Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 64:315\u2013319","journal-title":"Clin Nephrol"},{"key":"830_CR6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/ard.52.8.613","volume":"52","author":"Seideman","year":"1993","unstructured":"Seideman P, Muller-Suur R (1993) Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Ann Rheum Dis 52:613\u2013615","journal-title":"Ann Rheum Dis"},{"key":"830_CR7","first-page":"38","volume":"22","author":"Kremer","year":"1995","unstructured":"Kremer JM, Petrillo GF, Hamilton RA (1995) Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6\u00a0months of therapy. J Rheumatol 22:38\u201340","journal-title":"J Rheumatol"},{"key":"830_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000192391","volume":"55","author":"Kolli","year":"2009","unstructured":"Kolli VK, Abraham P, Isaac B, Selvakumar D (2009) Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy 55:83\u201390","journal-title":"Chemotherapy"},{"key":"830_CR9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/08860220500244823","volume":"27","author":"Devrim","year":"2005","unstructured":"Devrim E, Cetin R, Kilicoglu B et al (2005) Methotrexate causes oxidative stress in rat kidney tissues. Ren Fail 27:771\u2013773","journal-title":"Ren Fail"},{"key":"830_CR10","doi-asserted-by":"crossref","unstructured":"Abraham P, Kolli VK, Rabi S (o J) Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochem Funct 28:426\u2013433","DOI":"10.1002\/cbf.1676"},{"key":"830_CR11","first-page":"2072","volume":"22","author":"Kremer","year":"1995","unstructured":"Kremer JM, Hamilton RA (1995) The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5\u00a0mg. J Rheumatol 22:2072\u20132077","journal-title":"J Rheumatol"},{"key":"830_CR12","first-page":"15","volume":"12","author":"Evans","year":"1985","unstructured":"Evans WE, Christensen ML (1985) Drug interactions with methotrexate. J Rheumatol Suppl 12(Suppl 12):15\u201320","journal-title":"J Rheumatol Suppl"},{"key":"830_CR13","first-page":"218","volume":"22","author":"Rheumatoid","year":"1995","unstructured":"Rheumatoid Arthritis Clinical Trial Archive Group (1995) The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 22:218\u2013223","journal-title":"J Rheumatol"},{"key":"830_CR14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1179\/acb.2006.028","volume":"61","author":"Boey","year":"2006","unstructured":"Boey O, Van Hooland S, Woestenburg A et al (2006) Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg 61:166\u2013169","journal-title":"Acta Clin Belg"},{"key":"830_CR15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/ndt\/16.5.1087","volume":"16","author":"Boulanger","year":"2001","unstructured":"Boulanger H, Launay-Vacher V, Hierniaux P et al (2001) Severe methotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis. Nephrol Dial Transplant 16:1087","journal-title":"Nephrol Dial Transplant"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-011-0830-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-011-0830-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-011-0830-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T15:59:06Z","timestamp":1560355146000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-011-0830-6"}},"subtitle":["Dosisabh\u00e4ngigkeit, Komorbidit\u00e4t und Komedikation","Dose-dependency, comorbidities and comedication"],"short-title":[],"issued":{"date-parts":[[2011,7,8]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s00393-011-0830-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,8]]}}}